Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT04073810

Residual Inflammation and Plaque Progression Long-term Evaluation

Status
Active Not Recruiting
Phase
Study type
Observational
Enrollment
40 (estimated)
Sponsor
University of Cambridge · Academic / Other
Sex
All
Age
18 Years – 99 Years
Healthy volunteers
Not accepted

Summary

Inflammation drives atherosclerotic plaque rupture triggering most acute coronary syndromes. Despite advances in diagnosis and management of atherosclerosis, patients with myocardial infarction (MI) remain at increased risk of recurrent events. The RIPPLE study aims to examine the relationship between residual coronary inflammation detected by 68Ga-DOTATATE PET in patients treated for MI to long-term plaque progression measured by CT coronary angiography (CTCA). The association between infarct-related myocardial 68Ga-DOTATATE PET and myocardial function and viability will also be assessed.

Detailed description

While vascular inflammation can be detected using 18F-FDG PET, this method lacks inflammatory cell specificity and is unreliable for coronary imaging because of high background signals from the myocardium. Upregulation of somatostatin receptor subtype-2 (SST2) occurs in activated macrophages, offering a novel inflammation imaging target. 68Ga-DOTATATE, an SST2 PET tracer with low myocardial binding, shows promise for imaging coronary inflammation. Having previously demonstrated increased 68Ga-DOTATATE signals in coronary atherosclerotic lesions post-MI, we now aim to study the natural history of residual arterial inflammation in non-culprit arteries and better understand how 68Ga-DOTATATE signals relate to plaque morphology, progression and rupture. Residual infarct-related myocardial inflammation and its association with ischemic myocardial remodelling will also be examined.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTPET imagingCoronary 68Ga-DOTATATE PET-MRI or PET-CT at baseline and 3 months
DIAGNOSTIC_TESTCoronary CT angiographyCTCA at baseline and 2 years
DIAGNOSTIC_TESTCardiac MRICardiac MRI at 1 year

Timeline

Start date
2020-10-01
Primary completion
2024-12-01
Completion
2025-04-01
First posted
2019-08-29
Last updated
2024-07-19

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT04073810. Inclusion in this directory is not an endorsement.